Cellulitis is a common problem encountered in both outpatient and inpatient medicine and is a large contributor to healthcare expenditure. The best way to cut down on spending due to lengthy hospital stays and high readmission rates is to improve diagnostic accuracy, prescribe effective antibiotics, and address underlying risk factors for development of cellulitis. Patients with risk factors such as stasis dermatitis should be regularly checked for the development of infection. Current antibiotic choice for cellulitis infections is guided by the commonly suspected pathogens: Staphylococcus aureus and Group A Streptococcus. Patients who do not respond to outpatient therapy or who meet SIRS criteria should be considered for inpatient therapy. New emerging treatment options have become available that have proven to be very effective. This ranges from a once weekly antibiotic, Dalbavancin, to one that can effectively eradicate the infection with one dose; Oritavancin. These new antibiotic choices can improve patient adherence to treatment and help reduce antibiotic resistant infections.